Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2017 in bone metastases
NCT06380881Phase 1Completed
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- May 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-2017 in bone metastases, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Maximum Plasma Concentration at 169 days, Time to Maximum Plasma Concentration at 169 days and 7 more. Started May 2024; status: completed.
02
Drugs
SHR-2017
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT06380881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06380881.